Digestive health

PPIs, Bone Density, and Fracture Risk

Save

Bone questions come up alongside a handful of other long-term PPI concerns — kidney function, vitamin and mineral levels, infection risk, even dementia — all resting on the same kind of evidence: large database studies that can spot a pattern but can't isolate what caused it. A 2017 expert review from the American Gastroenterological Association weighed that evidence directly and reached a measured, not alarming, verdict.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Where the Bone Concern Comes From

Bone strength depends partly on calcium, and calcium absorption depends partly on stomach acid — specifically for calcium carbonate, one of the common dietary and supplemental forms, which needs an acidic environment to dissolve before the body can take it up. Long-term acid suppression is a plausible enough mechanism that researchers went looking for a real-world signal, and several large database studies, some following populations for a decade or more, reported that people on long-term PPIs had somewhat higher rates of hip, spine, and wrist fractures than people who weren't.

That kind of signal is worth taking seriously. It is not, on its own, proof that the medication caused the fractures. A database study can show two things trending together; it can't show which one is driving the other, or whether something else entirely is driving both. That distinction sounds academic, but it's the whole reason the guidance below doesn't land where a scary headline usually does.

What a Database Signal Can't Settle

People who stay on a PPI for years are frequently not a random slice of the population to begin with. They tend to be older, to carry more chronic conditions, and to take more medications overall — all things that independently raise fracture risk regardless of what's happening with stomach acid. Sorting out how much of the fracture signal belongs to the drug versus how much belongs to who ends up taking it long-term is a genuinely difficult statistical problem, and it's one epidemiologists openly disagree about.

This is sometimes called confounding by indication, and it shows up across nearly every long-term-medication safety question, not just this one. A raw comparison between PPI users and non-users is rarely a fair comparison, because the two groups were probably never starting from the same baseline health, no matter how carefully a study tries to adjust for age and other conditions afterward.

What the Expert Review Actually Concluded

The same 2017 American Gastroenterological Association review that covers long-term PPI safety broadly took on the bone and fracture question directly, and its verdict didn't match the tone of most headlines about it: when a PPI is appropriately indicated, the benefits generally outweigh the risks, and there is insufficient evidence to recommend routine strategies — bone density scans included — to mitigate these purported harms 1. A professional society reviewed the same fracture data driving the concern and stopped short of recommending universal bone-density screening for anyone on a long-term PPI.

The review's practical guidance sidesteps the unresolved science entirely: patients on a PPI should be on the lowest dose that controls symptoms, for no longer than genuinely needed 1. That advice holds regardless of whether the bone-fracture link turns out to be causal, confounded, or somewhere in between — it doesn't require the science to be settled before it's useful.

Who Should Stay On a PPI Despite This, and Who Should Revisit It

A separate 2022 AGA update on de-prescribing draws the practical line for this exact situation: people without a clear ongoing reason for a PPI are reasonable candidates to try stopping or stepping down, while people with erosive esophagitis, Barrett's esophagus, or a documented bleeding-risk indication should generally stay on it 2. A bone-density concern belongs in that conversation as one input, not as a reason on its own to override a documented medical need.

Barrett's esophagus makes the tradeoff concrete: guideline authors recommend continuing PPI therapy for patients who have it, since it's part of managing the only known precursor to esophageal adenocarcinoma 3. Someone in that position weighing a debated fracture association against a well-established cancer-precursor risk is not making the same calculation as someone taking a PPI reflexively for reflux that quieted down on its own years ago.

Why Omeprazole Gets Prescribed Long-Term in the First Place

Classic heartburn and regurgitation without alarm features typically starts with an eight-week trial of a once-daily PPI, and endoscopy gets reserved for people who don't improve, who develop alarm symptoms, or who carry risk factors that raise concern for Barrett's esophagus 4. Plenty of people finish that trial and stop; others find reflux returns reliably enough, and predictably enough, that continuing on the medication is the more practical path forward.

NIDDK frames PPIs as one option inside a wider GERD treatment picture that also includes lifestyle changes, antacids, and H2 blockers, with surgery kept in reserve for reflux nothing else controls 5. Bone density is only one of several questions that surface once someone has been on that treatment for years — how worried to be about long-term PPI use gets asked just as often about vitamin and mineral levels, kidney function, and even dementia, each requiring its own answer rather than a single verdict covering all of them.

The Bone Question Alongside Other Long-Term PPI Questions

Fracture risk rarely gets asked about in isolation. The same body of observational research that raised bone questions also produced separate literatures on whether PPIs cause vitamin deficiency, whether they raise infection risk, whether omeprazole causes kidney problems, and whether long-term use is tied to dementia — distinct questions with distinct mechanisms, not variations on one underlying theme.

A debated link on one long-term PPI question doesn't settle any of the others — each rests on its own evidence and deserves its own answer. Anyone weighing whether to keep taking a PPI long-term, and wondering about tapering off a PPI if the answer is no, is better served treating each of these questions on its own terms than assuming one verdict resolves them all. That's a conversation about sequencing and timing with a clinician, not a decision to reverse-engineer from a single debated fracture statistic.

Common questions

Not automatically. The expert review of this evidence found insufficient grounds to recommend routine bone density screening for everyone on a long-term PPI. Screening makes more sense when someone already has other osteoporosis risk factors — age, family history, prior fracture, low body weight — which is a conversation to have with a clinician rather than a blanket rule tied to the medication alone.

Possibly, in principle — calcium citrate doesn't need stomach acid to dissolve the way calcium carbonate does, so it's sometimes suggested as an alternative for people on long-term acid suppression. Whether switching forms meaningfully changes fracture risk hasn't been proven, but it's a reasonable, low-risk question to raise with a clinician or pharmacist.

There's no firm cutoff in the evidence, but the studies raising concern generally looked at continuous use measured in years, not weeks or months. Someone using a PPI briefly for an ulcer is in a different position than someone who has taken one daily, uninterrupted, for five years or more without a recent reassessment.

H2 blockers suppress stomach acid less aggressively than PPIs, so the theoretical effect on calcium absorption is generally considered smaller, though direct head-to-head fracture data comparing the two is limited. Switching medications purely to address a bone concern is worth discussing with a clinician rather than deciding independently.

Osteoporosis itself typically causes no symptoms until a fracture happens, which is part of why screening relies on bone density testing rather than how someone feels. A fracture from a minor fall or bump, new back pain with height loss, or a stooped posture developing over time are all reasons to bring bone health up with a clinician.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When Bone Symptoms on a PPI Need Medical Follow-Up

  • —a fracture from a minor fall or bump that wouldn't normally cause one
  • —new back pain with a noticeable loss of height
  • —a gradually stooped posture developing over months or years
  • —a family history of osteoporosis combined with several years of continuous PPI use

Severe pain, visible deformity, or inability to bear weight after a fall are reasons to go to an emergency room rather than wait for a scheduled appointment.

This article is educational and does not replace an evaluation by a clinician who can review bone health, history, and medications together.

References

  1. 1.Freedberg DE, Kim LS, Yang YX (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. doi:10.1053/j.gastro.2017.01.031 ✓Supports a balanced statement on long-term PPI risk/benefit, including purported bone/fracture risk, and dose minimization when medication is genuinely indicated.
  2. 2.Targownik LE, Fisher DA, Saini SD (2022). AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. PMID 35183361 ✓Supports which patients should attempt to stop or step down a PPI and which should continue.
  3. 3.Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022). Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. American Journal of Gastroenterology. doi:10.14309/ajg.0000000000001680Supports the recommendation for PPI therapy in patients with Barrett's esophagus as a reason to continue treatment.
  4. 4.Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022). ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. doi:10.14309/ajg.0000000000001538 ✓Supports the empiric-PPI-trial-first pathway and the indications for endoscopy in reflux.
  5. 5.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020). Treatment for GER & GERD. NIDDK, National Institutes of Health. link ✓Supports the enumeration of GERD treatment categories, including PPIs alongside lifestyle changes and other medications.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library